请输入您要查询的百科知识：

　

词条 Draft:Pierre Charneau
释义

  1. Pierre Charneau

  2. Education

  3. Career & Research

  4. Awards & Honors

  5. Selected Publications

  6. See also

  7. External Links

  8. References

{{AFC submission|d|v|u=BiotechScribbler|ns=118|decliner=StraussInTheHouse|declinets=20190203235639|ts=20190201153624}} {{AFC comment|1=Education unsourced, as is a large paragraph of the following section. Cite it or cut it. SITH (talk) 23:56, 3 February 2019 (UTC)}}

Pierre Charneau

Pierre Charneau (PhD) is a French Scientist and Inventor and Head of the [https://research.pasteur.fr/en/team/molecular-virology-and-vaccinology/ Molecular Virology and Vaccinology Unit (VMV)] at the Pasteur Institute and an acknowledged specialist of HIV, lentiviral gene transfer vectors and their medical applications. His discovery of the central DNA-Flap structure (Zennou et al, Cell, 2000.[1]) in the HIV genome, and its role in viral entry into the nucleus of the infected cell, grounded the optimization of lentiviral vectors and paved the way to more than 20 years of development in gene therapy and vaccines based on this gene delivery technology.

Pierre Charneau has published more than 100 research articles and holds 25 patents in the field of HIV and lentiviral vectors.

Education

Pierre Charneau studied at the Pierre and Marie Curie University (UPMC) in Paris from which he holds a research doctorate in Molecular and Cellular Biology (1995)[2].

After a short undergraduate research at the Curie Institute, he pursued his phD thesis[3] in Professor Luc Montagnier’s Viral Oncology Lab at the Pasteur Institute[4][5], on reverse transcription[6], nuclear import and mitosis-independent integration of HIV genome.

Career & Research

After completing his PhD, Charneau stayed in Montagnier’s lab where he became a Group Leader on Molecular Virology until 1999.

His research led to the discovery and characterization of the central DNA flap structure within the HIV genome and its key function in nuclear import of the lentivirus/HIV genome in non-dividing cells[7]. This discovery enabled the development of lentiviral vectors that can infect non-dividing cells[8], contrary to other types of retroviral gene transfer vectors, which can only target dividing cells. Since 2000, Charneau has led his own research group at the Pasteur Institute focusing on molecular virology and vectorology[9]. His research has specialized in lentiviral vectors medicinal applications and his publications[10] and patents[11] have led to extensive developments in gene therapy, as well as prophylactic and therapeutic vaccinations in infectious diseases and oncology.

Charneau’s development of lentiviral vectors are used in many therapeutic approaches such as carried out by BluebirdBio (Gene therapy[12][13], CAR-T[14]), Novartis[15] (CAR-T[16]), Kite[17] (TCR), Immune Design[18] (Cancer Vaccines) and TheraVectys[19][20][21] (Vaccines), a spin-off of the Pasteur Institute which was founded by Charneau himself in 2005.

Additionally, many research tools have since then been developed and adopted by the industry as well as academia with a wide number of peer-reviewed papers using the lentiviral vector technology[22]

Awards & Honors

2004 Award of the French Academy of Science – Prix Jean-Pierre Lecocq[23]

2005 Prize winner OSEO “Création-développement” - Concours d’aide à la creation d’entreprise de technologies innovantes, a contest for the creation of innovative technology companies

2009 Line Renaud Award of the [https://www.frm.org/en Fondation pour la Recherche Médicale][24]

Selected Publications

Zennou V, Petit C, Guetard D, Nerhbass U, Montagnier L, Charneau P. HIV-1 genome nuclear import is mediated by a central DNA flap. Cell. 2000 Apr 14;101(2):173-85.

Sirven A, Pflumio F, Zennou V, Titeux M, Vainchenker W, Coulombel L, Dubart-Kupperschmitt A, Charneau P. The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells. Blood. 2000 Dec15;96(13):4103-10.

Giannini C, Morosan S, Tralhao JG, Guidotti JE, Battaglia S, Mollier K, Hannoun L, Kremsdorf D, Gilgenkrantz H, Charneau P. A highly efficient, stable, and rapid approach for ex vivo human liver gene therapy via a FLAP lentiviral vector. Hepatology. 2003 Jul;38(1):114-22.

Arhel N, Genovesio A, Kim KA, Miko S, Perret E, Olivo-Marin JC, Shorte S, Charneau P. Quantitative four-dimensional tracking of cytoplasmic and nuclear HIV-1 complexes. Nat Methods. 2006 Oct;3(10):817-24. PubMed PMID: 16990814.

Iglesias MC, Mollier K, Beignon AS, Souque P, Adotevi O, Lemonnier F, Charneau P. Lentiviral vectors encoding HIV-1 polyepitopes induce broad CTL responses in vivo. Mol Ther. 2007 Jun;15(6):1203-10.

Arhel NJ, Souquere-Besse S, Munier S, Souque P, Guadagnini S, Rutherford S, Prévost MC, Allen TD, Charneau P. HIV-1 DNA Flap formation promotes uncoating of the pre-integration complex at the nuclear pore. EMBO J. 2007 Jun 20;26(12):3025-

Firat H, Zennou V, Garcia-Pons F, Ginhoux F, Cochet M, Danos O, Lemonnier FA, Langlade-Demoyen P, Charneau P. Use of a lentiviral flap vector for induction of CTL immunity against melanoma. Perspectives for immunotherapy. J Gene Med. 2002 Jan-Feb;4(1):38-45.

Iglesias MC, Frenkiel MP, Mollier K, Souque P, Despres P, Charneau P. A single immunization with a minute dose of a lentiviral vector-based vaccine is highly effective at eliciting protective humoral immunity against West Nile virus. J Gene Med. 2006 Mar;8(3):265-74.

Beignon AS, Mollier K, Liard C, Coutant F, Munier S, Rivière J, Souque P, Charneau P. Lentiviral vector-based prime/boost vaccination against AIDS: pilot study shows protection against Simian immunodeficiency virus SIVmac251 challenge in macaques. J Virol. 2009 Nov;83(21):10963-74.

Coutant F, Sanchez David RY, Félix T, Boulay A, Caleechurn L, Souque P,Thouvenot C, Bourgouin C, Beignon AS, Charneau P. A nonintegrative lentiviral vector-based vaccine provides long-term sterile protection against malaria. PLoS One. 2012;7(11):e48644..

Coutant F, Frenkiel MP, Despres P, Charneau P. Protective antiviral immunity conferred by a nonintegrative lentiviral vector-based vaccine. PLoS One. 2008;3(12):e3973

F. Di Nunzio, T. Félix, N.J. Arhel, S. Nisole, P. Charneau, A-S. Beignon, HIV-derived vectors for therapy and vaccination against HIV, In Vaccine, Volume 30, Issue 15, 2012, Pages 2499-2509, ISSN 0264-410X.

García-Nicolás, O.; Ricklin, M.E.; Liniger, M.; Vielle, N.J.; Python, S.; Souque, P.; Charneau, P.; Summerfield, A. A Japanese Encephalitis Virus Vaccine Inducing Antibodies Strongly Enhancing In Vitro Infection Is Protective in Pigs. Viruses 2017, 9, 124.

See also

Retinal gene therapy using lentiviral vectorsViral vector#LentivirusesViral vectorLentiviral vector in gene therapyChimeric antigen receptor

External Links

[https://research.pasteur.fr/en/team/molecular-virology-and-vaccinology/ Molecular Virology and Vaccinology Unit]

[https://labiotech.eu/sponsored/lentiviral-vectors-the-secret-behind-car-t/ Lentiviral vectors: the secret behind the rise of CAR-T therapies]

[https://labiotech.eu/sponsored/lentiviral-vector-vaccinations-theravectys/ Can Lentiviral Vectors Give CAR-T a Run for Its Money?]

[https://labiotech.eu/sponsored/current-landscape-immunotherapies-infographic/ Infographic: Discovering The Current Landscape of Immunotherapies]

References

1. ^{{Cite journal|last=Charneau|first=Pierre|last2=Montagnier|first2=Luc|last3=Nerhbass|first3=Ulf|last4=Guetard|first4=Denise|last5=Petit|first5=Caroline|last6=Zennou|first6=Véronique|date=2000-04-14|title=HIV-1 Genome Nuclear Import Is Mediated by a Central DNA Flap|url=https://www.cell.com/cell/abstract/S0092-8674(00)80828-4|journal=Cell|language=English|volume=101|issue=2|pages=173–185|doi=10.1016/S0092-8674(00)80828-4|issn=0092-8674|pmid=10786833}}
2. ^https://fr.linkedin.com/in/pierre-charneau-49829749
3. ^{{Cite journal|last=Charneau|first=Pierre|last2=Borman|first2=Andrew M.|last3=Quillent|first3=Caroline|last4=Guétard|first4=Denise|last5=Chamaret|first5=Sophie|last6=Cohen|first6=Jacques|last7=Rémy|first7=Gérard|last8=Montagnier|first8=Luc|last9=Clavel|first9=François|date=1994-11-15|title=Isolation and Envelope Sequence of a Highly Divergent HIV-1 Isolate: Definition of a New HIV-1 Group|url=http://www.sciencedirect.com/science/article/pii/S0042682284716400|journal=Virology|volume=205|issue=1|pages=247–253|doi=10.1006/viro.1994.1640|pmid=7975221|issn=0042-6822}}
4. ^{{Cite web|url=https://www.ladepeche.fr/article/2000/05/05/98265-le-virus-du-sida-pour-soigner-le-cancer.html|title=Le virus du sida pour soigner le cancer|website=ladepeche.fr|language=fr|access-date=2019-02-04}}
5. ^{{Cite news|url=https://www.sciencesetavenir.fr/sciences/quand-le-virus-transporte-des-genes-medicaments_513|title=Quand le virus transporte des gènes-médicaments|work=Sciences et Avenir|access-date=2019-02-04|language=fr}}
6. ^{{Cite journal|last=Charneau|first=Pierre|last2=Mirambeau|first2=Gilles|last3=Roux|first3=Pascal|last4=Paulous|first4=Sylvie|last5=Buc|first5=Henri|last6=Clavel|first6=François|date=1994-09-01|title=HIV-1 Reverse Transcription A Termination Step at the Center of the Genome|url=http://www.sciencedirect.com/science/article/pii/S0022283684715427|journal=Journal of Molecular Biology|volume=241|issue=5|pages=651–662|doi=10.1006/jmbi.1994.1542|pmid=7520946|issn=0022-2836}}
7. ^{{Cite journal|last=Charneau|first=Pierre|last2=Montagnier|first2=Luc|last3=Nerhbass|first3=Ulf|last4=Guetard|first4=Denise|last5=Petit|first5=Caroline|last6=Zennou|first6=Véronique|date=2000-04-14|title=HIV-1 Genome Nuclear Import Is Mediated by a Central DNA Flap|url=https://www.cell.com/cell/abstract/S0092-8674(00)80828-4|journal=Cell|language=English|volume=101|issue=2|pages=173–185|doi=10.1016/S0092-8674(00)80828-4|issn=0092-8674|pmid=10786833}}
8. ^{{Cite journal|last=Charneau|first=Pierre|last2=Dubart-Kupperschmitt|first2=Anne|last3=Coulombel|first3=Laure|last4=Vainchenker|first4=William|last5=Titeux|first5=Monique|last6=Zennou|first6=Véronique|last7=Pflumio|first7=Françoise|last8=Sirven|first8=Aude|date=2000-12-15|title=The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells|url=http://www.bloodjournal.org/content/96/13/4103|journal=Blood|language=en|volume=96|issue=13|pages=4103–4110|issn=0006-4971|pmid=11110680}}
9. ^{{Cite web|url=https://research.pasteur.fr/en/team/molecular-virology-and-vaccinology/|title=Molecular Virology and Vaccinology • Research|last=Pasteur|first=research pasteur fr-Institut|website=Research|language=en-US|access-date=2019-01-30}}
10. ^{{Cite web|url=https://www.ncbi.nlm.nih.gov/pubmed/?term=Charneau+P%5BAuthor%5D|title=Charneau P[Author] - PubMed - NCBI|last=pubmeddev|website=www.ncbi.nlm.nih.gov|language=en|access-date=2019-02-04}}
11. ^{{Cite web|url=https://patents.justia.com/inventor/pierre-charneau|title=Pierre Charneau Inventions, Patents and Patent Applications - Justia Patents Search|website=patents.justia.com|access-date=2019-02-04}}
12. ^{{Cite web|url=https://www.sec.gov/Archives/edgar/data/1293971/000119312513219925/d500108ds1.htm|title=S-1|website=www.sec.gov|access-date=2019-01-30}}
13. ^{{Cite web|url=https://www.businesswire.com/news/home/20181203006016/en/bluebird-bio-Presents-New-Data-LentiGlobin-Gene|title=bluebird bio Presents New Data for LentiGlobin Gene Therapy in Transfusion Dependent β-Thalassemia at 60th Annual Meeting of the American Society of Hematology|date=2018-12-04|website=www.businesswire.com|language=en|access-date=2019-01-30}}
14. ^{{Cite web|url=http://investor.bluebirdbio.com/node/9741/html|title=SEC Filing {{!}} bluebird bio, Inc.|website=investor.bluebirdbio.com|access-date=2019-01-30}}
15. ^{{Cite web|url=https://www.businesswire.com/news/home/20170502005316/en/bluebird-bio-Licenses-Lentiviral-Vector-Patent-Rights|title=bluebird bio Licenses Lentiviral Vector Patent Rights for Development and Commercialization of Cell Therapies|date=2017-05-02|website=www.businesswire.com|language=en|access-date=2019-01-30}}
16. ^{{Cite web|url=https://www.novartis.com/news/media-releases/novartis-receives-first-ever-fda-approval-car-t-cell-therapy-kymriahtm-ctl019|title=Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice|website=Novartis|language=en|access-date=2019-01-30}}
17. ^{{Cite web|url=http://investor.bluebirdbio.com/news-releases/news-release-details/kite-pharma-and-bluebird-bio-announce-strategic-collaboration|title=Kite Pharma and bluebird bio Announce Strategic Collaboration to Advance Second Generation TCR Cell Therapy Products to Treat HPV-Associated Cancers|website=bluebird bio, Inc.|language=en|access-date=2019-01-30}}
18. ^{{Cite web|url=https://thefly.com/landingPageNews.php?id=2448029&headline=IMDZ-Immune-Design-enters-settlement-license-pacts-with-TheraVectys|title=Immune Design enters settlement, license pacts with TheraVectys IMDZ - The Fly|website=thefly.com|access-date=2019-01-30}}
19. ^{{Cite web|url=https://labiotech.eu/medical/theravectys-hiv-cure-on-the-road-to-success/|title=Theravectys' HIV Cure on the Road to Success|date=2015-07-20|website=Labiotech.eu|language=en-US|access-date=2019-01-30}}
20. ^{{Cite web|url=https://labiotech.eu/medical/immunotherapy-reaches-breakthrough-in-eliminating-hiv/|title=Immunotherapy reaches Breakthrough in eliminating HIV|date=2016-06-13|website=Labiotech.eu|language=en-US|access-date=2019-01-30}}
21. ^{{Cite web|url=https://labiotech.eu/infographics/hiv-treatments-aids-europe/|title=The 10 Most Innovative HIV Treatments to Defeat AIDS|date=2017-09-13|website=Labiotech.eu|language=en-US|access-date=2019-01-30}}
22. ^{{Cite journal|last=Ikeda|first=Yasuhiro|last2=Barry|first2=Michael A.|last3=Sakuma|first3=Toshie|date=2012-05-01|title=Lentiviral vectors: basic to translational|url=http://www.biochemj.org/content/443/3/603|journal=Biochemical Journal|language=en|volume=443|issue=3|pages=603–618|doi=10.1042/BJ20120146|issn=0264-6021|pmid=22507128}}
23. ^{{Cite web|url=http://www.academie-sciences.fr/archivage_site/activite/prix/laureat_04.pdf|title=|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}
24. ^{{Cite web|url=https://www.frm.org/upload/pdf/frm-cp-prix-09.pdf|title=2009 Awards by the Fondation pour la Recherche Médicale|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}
{{authority control}}{{AFC submission|||ts=20190204214138|u=BiotechScribbler|ns=118}}
随便看

　

开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。

　

Copyright © 2023 OENC.NET All Rights Reserved
京ICP备2021023879号 更新时间：2024/11/11 8:40:49